Evidence map›Paper›PMID 29527563›Full record

ArticleEJNMMI radiopharmacy and chemistry2017

[

Andreas Poschenrieder, Margret Schottelius, Theresa Osl, Markus Schwaiger, Hans-Jürgen Wester

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andreas Poschenrieder1Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meißner-Str.3, 85748 Garching, Germany.
Margret Schottelius1Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meißner-Str.3, 85748 Garching, Germany.
Theresa Osl1Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meißner-Str.3, 85748 Garching, Germany.
Markus Schwaiger2Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675 Munich, Germany.
Hans-Jürgen Wester1Pharmaceutical Radiochemistry, Technische Universität München, Walther-Meißner-Str.3, 85748 Garching, Germany.
Technical University of Munich · DEKlinikum rechts der Isar · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a

methodsFor this purpose, 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), or 1,4,7-triazacyclononane-triacetic acid (NOTA) was conjugated to the highly affine CXCR4-targeting pentixather scaffold. Affinities were determined using Jurkat T-lymphocytes in competitive binding assays employing [

results[

conclusions[

Indexed as

64CuCancerCXCR4GPCRNOTAPentapeptidePETRadiopharmaceuticalTheranosticTracer

Identifiers

PMID29527563
PMCPMC5835975
OpenAlexW2577150938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.